Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydrocodone/paracetamol (Primary) ; VX 993 (Primary)
Indications Acute pain
Focus Therapeutic Use
Sponsors Vertex Pharmaceuticals

Most Recent Events

26 Jun 2025 Status changed from active, no longer recruiting to completed.
15 Jun 2025 Status changed from recruiting to active, no longer recruiting.
05 May 2025 According to Vertex Pharmaceuticals media release, Vertex expects to complete the Phase 2 study for an oral formulation of VX-993 this quarter.Vertex expects to report results from the Phase 2 study in the second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com